Table 1.
Characteristics of AL-amyloidosis patients and plasma cell clones
| Feature | Frequency |
|---|---|
| Age, y, median (range) | 59 (34-82) |
| Men, no. (%) | 28 (58) |
| Biopsies with amyloid per patient, median no. (range) | 2 (1-4) |
| Patients with 2 or more organs involved, no. (%) | 26 (54) |
| Patients with cardiac involvement, no. (%) | 29 (60) |
| Brain natriuretic peptide, median pg/mL (range) | 710 (30-4210) |
| Patients with renal involvement, no. (%) | 35 (73) |
| Urinary protein, median mg/d (range) | 3052 (514-13,224) |
| Serum albumin, median g/L (range) | 37 (19-50) |
| β2 microglobulin, median mg/L (range) | 246.5 (127.5-1623.5) |
| Marrow specimens at diagnosis and relapse* | 40/11 |
| Plasma cells in marrow specimens, median % (range) | 9 (2-34) |
| Patients with serum M-spike, no. (%) | 20 (42) |
| Patients with M-spike, median g/dL, no. (range) | 1.1 (0.2-2.7) |
| Patients with IgG kappa, no. | 1 |
| Patients with IgG lambda, no. | 16 |
| Patients with IgA kappa, no. | 2 |
| Patients with IgA lambda, no. | 1 |
| Patients with Kappa light chain only, no. | 6 |
| Patients with Lambda light chain only, no. | 22 |
| Patients with abnormal FLC ratio†, no. (%) | 47 (98) |
| Patients with abnormal lambda FLC, no. (%) | 41 (85) |
| Lambda FLC, median mg/dL (range) | 16.3 (2.36-366.5) |
| Patients with abnormal kappa FLC, no. (%) | 7 (15) |
| Kappa FLC, median mg/dL (range) | 73 (3.58-290) |
*
Three patients provided 2 samples each, 2 at diagnosis and relapse and 1 at first and second relapse, for a total of 51 specimens.
†
Free light chains (FLCs) by FreeLite assay (Comenzo5).